University of California, Los Angeles
This is a phase II open-label efficacy and safety study to evaluate standard of care treatment response measured by PET imaging radiotracer 68Ga-FAPI-46 in 120 subjects with SSc-ILD.
Inclusion Criteria: * Ability to provide written informed consent. * Male or female \> 18 years of age at the screening visit. * Meets the 2013 American College of Rheumatology (ACR)/EULAR Classification Criteria for SSc. * ILD confirmed by thoracic high resolution computed tomography (HRCT) at the baseline visit. * Initiated or will initiate a new ILD therapy within the last 3 months +/- 1 week prior to the screening visit. * If enrolled in the FAPI/PET group, women of child-bearing potential must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confi…
68Ga-FAPI-46 will be used for the PET/CT for SSc ILD patients
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.